GLSI vs. ABUS, KALV, KURA, BCAX, TSHA, VIR, TERN, RLAY, SIGA, and ORGO
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), Kura Oncology (KURA), Bicara Therapeutics (BCAX), Taysha Gene Therapies (TSHA), Vir Biotechnology (VIR), Terns Pharmaceuticals (TERN), Relay Therapeutics (RLAY), Siga Technologies (SIGA), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry.
Greenwich LifeSciences vs. Its Competitors
Arbutus Biopharma (NASDAQ:ABUS) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 20.3% of Arbutus Biopharma shares are held by company insiders. Comparatively, 51.7% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Greenwich LifeSciences has lower revenue, but higher earnings than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Greenwich LifeSciences, indicating that it is currently the more affordable of the two stocks.
Greenwich LifeSciences has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -352.24%. Arbutus Biopharma's return on equity of -59.28% beat Greenwich LifeSciences' return on equity.
Arbutus Biopharma has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.
Arbutus Biopharma currently has a consensus price target of $5.50, indicating a potential upside of 53.42%. Greenwich LifeSciences has a consensus price target of $42.00, indicating a potential upside of 247.39%. Given Greenwich LifeSciences' higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Arbutus Biopharma.
In the previous week, Greenwich LifeSciences had 19 more articles in the media than Arbutus Biopharma. MarketBeat recorded 22 mentions for Greenwich LifeSciences and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.20 beat Greenwich LifeSciences' score of 0.38 indicating that Arbutus Biopharma is being referred to more favorably in the media.
Summary
Arbutus Biopharma and Greenwich LifeSciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:GLSI) was last updated on 8/22/2025 by MarketBeat.com Staff
MarketBeat All Access